NCT02868541

Brief Summary

The objective of this project is to study the prevalence of viruses and bacteria responsible for transmissible acute respiratory infections in the respiratory tract of pilgrims returning from the trip. The patients included, will be the consultant pilgrims to the traveler health center, and before leaving for Hajj. Based on the results obtained in previous studies, it is estimated that 200 pilgrims will be included each year, 600 in total (inclusion period of 3 years). Respiratory secretions are then collected by nasal swab and throat (swab) prior to departure for the hajj. In return, patients will be reconvened systematic consultation to record medical events potentially encountered during the trip, and it will again be performed the same nasal swabs and throat. It will then be performed on these samples' return from hajj "molecular detection (PCR and RT-PCR) of 35 viruses and bacteria respiratory tropism: influenza (3), RSV (2), metapneumovirus (1), Coronavirus (4), Parainfluenzavirus (4), enteroviruses (4), rhinovirus (1), adenovirus (6) bocavirus, polyomavirus (2), pneumococcus, Bordetella pertussis, Mycoplasma pneumoniae, Chlamydophila pneumoniae, Haemophilus influenzae, Neisseria meningitidis and Coxiella burnetii. Samples "return of hajj" positive should be cultured for the isolation of the strain. For patients positive return, it will be done further research of these 35 viruses and bacteria on samples "start of hajj," the same method described above. In addition to this systematic consultation, and if symptoms return, the pilgrims will be seen in consultation for a diagnosis evaluation and therapeutic management. This study will shed light on the acquisition of microorganisms respiratory tropism during the stay and on the potential risks associated with the circulation of these pathogens after the trip.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
905

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jan 2017

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 11, 2016

Completed
5 days until next milestone

First Posted

Study publicly available on registry

August 16, 2016

Completed
5 months until next milestone

Study Start

First participant enrolled

January 25, 2017

Completed
2.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 6, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 6, 2019

Completed
Last Updated

October 28, 2022

Status Verified

October 1, 2022

Enrollment Period

2.6 years

First QC Date

August 11, 2016

Last Update Submit

October 26, 2022

Conditions

Keywords

microorganismspilgrimhajj

Outcome Measures

Primary Outcomes (1)

  • The number of new viruses and/or bacteria identified and characterized by respiratory and pharyngeal carriage among pilgrims between the departure and the return of Hajj

    up to 3 years

Study Arms (1)

Haaj pilgrim

Patient that are showing at the traveler hospital health center requiring the mandatory Meningococcal vaccine ACYW135

Other: Naso pharyngeal swab

Interventions

Naso pharyngeal swab

Haaj pilgrim

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Travelers pilgrims over 18 years leaving for the Hajj pilgrimage and consulting at the international vaccination service of the Public Assistance of Marseille Hositals for the mandatory meningococcal ACYW135 vaccination.

You may qualify if:

  • All travelers presenting during the study period in the service of international vaccination for mandatory meningococcal ACYW135 vaccination ,
  • Affiliated to a social security insurance regime
  • Male or Female
  • Aged over 18 years
  • Having signed informed consent form
  • able to understand and answer the study questions

You may not qualify if:

  • Patients aged under 18
  • Patient whose protocol compliance seems unlikely to investigator
  • Unable to understand the nature and objectives of the study,
  • Refusing to sign the informed consent form.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Assistance Publique Hopitaux de Marseille

Marseille, 13354, France

Location

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 11, 2016

First Posted

August 16, 2016

Study Start

January 25, 2017

Primary Completion

September 6, 2019

Study Completion

September 6, 2019

Last Updated

October 28, 2022

Record last verified: 2022-10

Locations